Explore

Search ClinicalTrials.gov

Find trials by condition, intervention, sponsor, or location. Filter by status, phase, and study type — or enter an NCT ID to jump straight to a trial.

Find trials by sponsor or company

Search by sponsors

RecruitingPhase IIIPhase III recruiting

StatusPhaseStudy typeSort

Results for “Merck”

Avelumab Program Rollover StudyActive Not Recruiting
NCT03815643Phase 3Updated Jun 29, 2026
Sponsor: EMD Serono Research & Development Institute, Inc.
Solid Tumors
United States, Argentina, Australia, Belgium, Brazil +17 more
A Study of the Effect of Diltiazem on the Plasma Levels of Nemtabrutinib (MK-1026-022)Completed
NCT07232589Phase 1Updated Jun 29, 2026
Sponsor: Merck Sharp & Dohme LLC
Healthy
United States
Experimental Human Pneumococcal Challenge With SPN3Completed
NCT05535868NAUpdated Jun 29, 2026
Sponsor: Liverpool School of Tropical Medicine
Streptococcus Pneumonia · Controlled Human Infection
United Kingdom
A Study of Nirogacestat in Japanese Adults With Desmoid Tumors/Aggressive Fibromatosis (DT/AF)Active Not Recruiting
NCT07170644Phase 2Updated Jun 29, 2026
Sponsor: SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany
Desmoid Tumor · Aggressive Fibromatosis
Japan
Pembrolizumab (MK-3475) Plus Investigational Agents in Resectable Non-small Cell Lung Cancer (NSCLC) (MK-3475-01E/KEYMAKER-U01)Recruiting
NCT06788912Phase 2Updated Jun 26, 2026
Sponsor: Merck Sharp & Dohme LLC
Lung Neoplasm Malignant
United States, Chile, Greece, Hungary, Italy +4 more
A Clinical Study to Evaluate the Safety, Tolerability and Efficacy of IOS-1002 Administered Alone and in Combination With Pembrolizumab, a PD-1 Monoclonal Antibody in Advanced Solid TumorsCompleted
NCT05763004Phase 1Updated Jun 26, 2026
Sponsor: ImmunOs Therapeutics AG
Solid Tumor, Adult
Australia
Coformulation of Pembrolizumab/Vibostolimab (MK-7684A) Versus Pembrolizumab (MK-3475) Monotherapy for Programmed Cell Death 1 Ligand 1 (PD-L1) Positive Metastatic Non-Small Cell Lung Cancer (MK-7684A-003, KEYVIBE-003)Completed
NCT04738487Phase 3Updated Jun 26, 2026
Sponsor: Merck Sharp & Dohme LLC
Lung Neoplasms · Non-Small-Cell Lung Carcinoma
United States, Brazil, Canada, Chile, China +18 more
KEYMAKER-U01 Substudy 3: Efficacy and Safety Study of Pembrolizumab (MK-3475) When Used With Investigational Agents in Participants With Advanced Non-small Cell Lung Cancer (NSCLC), Previously Treated With Anti-programmed Cell Death Receptor Ligand 1 (PD-L1) Therapy (MK-3475-01C/KEYMAKER-U01C)Completed
NCT04165096Phase 2Updated Jun 26, 2026
Sponsor: Merck Sharp & Dohme LLC
Carcinoma, Non-Small-Cell Lung
United States, Hungary, Israel, Italy, Poland +2 more
T Cells and Pembrolizumab for Recurrent and Newly Diagnosed GlioblastomaActive Not Recruiting
NCT06157541Phase 1, Phase 2Updated Jun 26, 2026
Sponsor: Queensland Institute of Medical Research
Glioblastoma Multiforme · Astrocytoma, Grade IV
Australia
KEYMAKER-U04 Substudy 04D: A Clinical Study of New Treatments Given With Enfortumab Vedotin and Pembrolizumab in People With Urothelial Cancer (MK-3475-04D/KEYMAKER-U04)Recruiting
NCT07232602Phase 1, Phase 2Updated Jun 26, 2026
Sponsor: Merck Sharp & Dohme LLC
Bladder Cancer
United States, Chile, France, Israel, Netherlands +3 more
Study of Pembrolizumab/Vibostolimab (MK-7684A) in Combination With Concurrent Chemoradiotherapy Followed by Pembrolizumab/Vibostolimab Versus Concurrent Chemoradiotherapy Followed by Durvalumab in Participants With Stage III Non-small Cell Lung Cancer (MK-7684A-006)Active Not Recruiting
NCT05298423Phase 3Updated Jun 26, 2026
Sponsor: Merck Sharp & Dohme LLC
Carcinoma, Non-Small-Cell Lung
United States, Argentina, Australia, Brazil, Chile +20 more
A Study to Evaluate Investigational Agents With or Without Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer Previously Exposed to Programmed Cell Death 1 Protein (PD-1)/ Programmed Cell Death Ligand 1 (PD-L1) Treatment (MK-3475-06B)Recruiting
NCT05319730Phase 1, Phase 2Updated Jun 26, 2026
Sponsor: Merck Sharp & Dohme LLC
Esophageal Squamous Cell Carcinoma
United States, Brazil, Chile, China, Germany +9 more
Enfortumab Vedotin + Pembrolizumab Induction to Spare the Bladder in MIBCNot Yet Recruiting
NCT07663747Phase 2Updated Jun 25, 2026
Sponsor: The Netherlands Cancer Institute
Urothelial Bladder Cancer
Netherlands
Study of Pembrolizumab (MK-3475) Versus Platinum-Based Chemotherapy for Participants With Programmed Cell Death-Ligand 1 (PD-L1)-Positive Advanced or Metastatic Non-Small Cell Lung Cancer (MK-3475-042/KEYNOTE-042)Completed
NCT02220894Phase 3Updated Jun 25, 2026
Sponsor: Merck Sharp & Dohme LLC
Non-small Cell Lung Cancer
pTVG-HP DNA Vaccine With or Without pTVG-AR DNA Vaccine and Pembrolizumab in Patients With Castration-Resistant, Metastatic Prostate CancerActive Not Recruiting
NCT04090528Phase 2Updated Jun 25, 2026
Sponsor: University of Wisconsin, Madison
Castration-resistant Prostate Cancer · Metastatic Cancer · Prostate Cancer
United States
ASTEROID: A Trial of ASTX660 in Combination With PembrolizumabActive Not Recruiting
NCT05082259Phase 1Updated Jun 25, 2026
Sponsor: Institute of Cancer Research, United Kingdom
Advanced Cancer · Cervical Cancer · Triple Negative Breast Cancer
United Kingdom
A Drug-Drug Interaction Study of Itraconazole and Opevesostat (MK-5684) in Healthy Adult Male Participants (MK-5684-017)Completed
NCT07548606Phase 1Updated Jun 25, 2026
Sponsor: Merck Sharp & Dohme LLC
Healthy
United States
A Study of BI-1206 in Combination With Pembrolizumab in Subjects With Advanced Solid TumorsRecruiting
NCT04219254Phase 1, Phase 2Updated Jun 25, 2026
Sponsor: BioInvent International AB
Solid Tumor, Adult
United States, Georgia, Germany, Poland, Romania +2 more
Pembrolizumab Plus Lenvatinib in Unresectable Cutaneous Angiosarcoma PatientsRecruiting
NCT06673628Phase 2Updated Jun 24, 2026
Sponsor: National Cancer Center, Japan
Angiosarcoma of Skin · Angiosarcoma Metastatic
Japan
A Clinical Trial of MK-4646 With Bictegravir/Emtricitabine/Tenofovir Alafenamide and Dolutegravir in Healthy Adult Participants (MK-4646)Active Not Recruiting
NCT07532304Phase 1Updated Jun 24, 2026
Sponsor: Merck Sharp & Dohme LLC
Healthy
United States
Study of the Selective PI3K-Beta Inhibitor GSK2636771 in Combination With Pembrolizumab in Patients With Metastatic Melanoma and PTEN LossActive Not Recruiting
NCT03131908Phase 1, Phase 2Updated Jun 24, 2026
Sponsor: M.D. Anderson Cancer Center
Melanoma and Other Malignant Neoplasms of Skin · Metastatic Melanoma
United States
A Study of Ulonivirine (MK-8507) and Methadone in Healthy Volunteers (MK-8507-019)Not Yet Recruiting
NCT07595263Phase 1Updated Jun 23, 2026
Sponsor: Merck Sharp & Dohme LLC
Healthy
Study of Olaparib (MK-7339) in Combination With Pembrolizumab (MK-3475) in the Treatment of Homologous Recombination Repair Mutation (HRRm) and/or Homologous Recombination Deficiency (HRD)-Positive Advanced Cancer (MK-7339-007/KEYLYNK-007)Completed
NCT04123366Phase 2Updated Jun 23, 2026
Sponsor: Merck Sharp & Dohme LLC
Solid Tumors
United States, Argentina, Australia, Canada, Colombia +18 more
Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab With or Without Platinum Chemotherapy in 1L Non-Small Cell Lung Cancer (TROPION-Lung07)Active Not Recruiting
NCT05555732Phase 3Updated Jun 23, 2026
Sponsor: Daiichi Sankyo
Metastatic Non Small Cell Lung Cancer
United States, Argentina, Australia, Austria, Belgium +24 more
Preoperative Pembrolizumab and Chemotherapy in Resectable, Recurrent HNSCCRecruiting
NCT05726370Phase 2Updated Jun 23, 2026
Sponsor: Dana-Farber Cancer Institute
Head and Neck Squamous Cell Carcinoma · Head and Neck Cancer · Resectable Head and Neck Squamous Cell Carcinoma · Recurrent Head and Neck Squamous Cell Carcinoma
United States

Previous page Next page